Role of 18F-FDG PET/CT in Gastric Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-01-31

Study Completion Date

2024-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of the study is to assess the value of PET/CT in diagnosis, staging, response evaluation, and relapse monitoring of gastric cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparing the Diagnostic Role of PET/MRI and of PET/CT Among Patients With Gastric Cancer

NCT03015298

Gastric Cancer Stage

UNKNOWN

Evaluating the Potential Usefulness of 18F-AlF-FAPI PET/CT in Patients With Gastrointestinal Tumors and Compared With 18F-FDG PET/CT

NCT05430841

Gastric Cancer Pancreatic Cancer Liver Cancer

COMPLETED NA

The Therapeutic Efficacy of 18F-FDG Combined With 18F-FAPI PET/MR in Neoadjuvant Therapy for Gastric Cancer

NCT06327386

Cancer

RECRUITING

Multi-parametric MRI and Dual-energy CT in Patients of Gastric Cancer

NCT05508126

Gastric Cancer Stage

RECRUITING

Post-treatment Ultrasensitive Positron Emission Tomography in Nasopharyngeal Carcinoma Patients

NCT04394091

Nasopharyngeal Carcinoma

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

gastric cancer (GC) is the fifth most common malignancy and the third leading cause of cancer mortality worldwide (1) It carries a poor prognosis, with a 5-year survival of only 20%-30% (2) Clinical staging, based mainly on imaging, is critical in determining the best treatment.There is a widely accepted consensus of the usefulness of FDG PET/CT in staging and restaging of gastric cancer. According to evidence-based data, this modality can evaluate gastric cancer more accurately and is helpful for evaluation of tumor biologic characteristics, detection of lymph node and distant metastases, assessment of tumor response to therapy(9).

retrospective and prospective study will conducted at Sohag oncology hospital, nuclear medicine unit\& Assuit university hospital, nuclear medicine unit including 50 patients in 12 months .

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastric Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

pet -ct

assessment of added value of pet -ct in patients with gastric cancer and how patient get benefit from this finding

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. patients diagnosed as GC on surgically resected specimens;
2. Patients with gastric and extragastric metastasis.
3. patients with gastric cancer either operated or not.

Exclusion Criteria

1. Patients with second malignancy.
2. Patient without proven pathology of cancer stomach.
3. Severely ill patient (patient with disturbed conscious level, or couldn't lay supine during the imaging).
4. uncontrolled diabetic patient with blood glucose level more than 200mg\\dl.
5. pregnant women

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No